Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480656 | 0.75 | KDM4E (0.53) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL19374980 | 0.73 | KDM4E (0.56) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL2449385 | 0.73 | KDM4E (0.51) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL2445185 | 0.70 | KDM4E (0.49) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL4058469 | 0.70 | KDM4E (0.42) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL13492907 | 0.70 | ADORA2A (0.36) | KDM4EMAPTPOLBMEN1KMT2A | |
| SCHEMBL9388600 | 0.69 | KDM4E (0.47) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL8174835 | 0.68 | NCOA1 (0.43) | KDM4EMAPTSMN1; SMN2POLBNCOA1 | |
| SCHEMBL18120283 | 0.68 | KDM4E (0.46) | KDM4EMAPTSMN1; SMN2POLBMEN1 | |
| SCHEMBL480760 | 0.66 | LMNA (0.67) | KDM4EMAPTSMN1; SMN2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2708538-A1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2014-03-19 | — | — | EP | disclosed |
| EP-2411393-B1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109287-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KDM4E 4718/4885MAPT 1998/4885SMN1; SMN2 2770/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | KDM4E 4677/4885MAPT 2007/4885SMN1; SMN2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.